SPOTLIGHT on a Postdoctoral Associate: Q&A: Ilsiya Ibragimova, PhD

ilsiya2Ilsiya Ibragimova is a postdoctoral associate in the Cancer Epigenetics Program, which focuses on the role of epigenetic deregulation in cancer and determines how that information can improve patient outcomes. After completing her MS in biochemistry at Kazan State University in Russia, Ibragimova began her work on a PhD in molecular biology. Continue Reading »

Small-Molecule Compound Shows Promise for Treating Drug-Resistant Tumors

spheres-1-revA new compound called ONC201/TIC10 has entered clinical trials and may have the potential to treat various forms of drug-resistant cancers. Through a screen of an NCI chemical library, Wafik S. El-Deiry, MD, PhD, FACP, professor of medical oncology and deputy director for translational research at Fox Chase Cancer Center, and his colleagues discovered ONC201/TIC10. Continue Reading »

Q&A: John A. Ridge, MD, PhD, FACS

Since joining Fox Chase in 1991 as chief of head and neck surgery, John A. Ridge has been dedicated to developing treatments and surgical techniques that cure head and neck cancers while allowing patients to maintain a high quality of life. Nationally recognized, Ridge focuses his clinical practice on head and neck and endocrine tumors, including nonsurgical management, organ preservation, new surgical techniques, and early and advanced thyroid tumors. As a co-chair of the National Cancer Institute’s Head and Neck Cancer Steering Committee, he helps coordinate and direct federally funded clinical research in the field, setting the agenda for the … Continue Reading »

Comments Off

Pancreatic Cancer Cells Hijack Vitamin D Receptor in Fight Against Chemotherapy

The Topline  Pancreatic cancer cells use the vitamin D receptor (VDR) to repair the damage caused by gemcitabine Treatments that inhibit VDR may render tumors more sensitive to cancer-killing drugs VDR appears to act epigenetically on RAD51 to fix DNA damage caused by chemotherapy and allow tumor cells to survive and continue dividing Pancreatic cancer is one of the deadliest forms of the disease. Doctors’ typical line of attack involves DNA-damaging agents such as gemcitabine, but despite the potent activities of these drugs, patient survival is only extended by a few months, if that. Indeed, pancreatic cancer has the lowest … Continue Reading »

Comments Off
Pictured from left to right are Stephen M. Sykes, Sergei Grivennikov, Neil Johnson, James S. Duncan, and Glenn F. Rall.

On the Cutting Edge with New Principal Investigators

Attracting and cultivating talented early-career scientists has long been a hallmark of the culture at Fox Chase. Glenn F. Rall, associate chief academic officer and co-leader of the Immune Cell Development and Host Defense Program, sat down with four recently hired researchers — James S. Duncan, Sergei Grivennikov, Neil Johnson, and Stephen M. Sykes — to talk about what’s exciting at the bench. Continue Reading »

Comments Off

Q&A: Stephen C. Rubin, MD

Stephen C. Rubin, MD, joined Fox Chase in March as chief of gynecologic oncology. A nationally known expert in the management of ovarian cancer, Rubin’s interests include minimally invasive gynecologic surgery, hereditary ovarian cancer, and ovarian cancer clinical trials.

Q: How did you decide on a career in gynecologic oncology?
You hear a lot about the merits of multidisciplinary cancer care, combining the various therapeutic disciplines – surgery, chemotherapy, and radiation therapy. Gynecologic oncology is the only true multidisciplinary Continue Reading »

Comments Off

Fox Chase-Temple Team Receives ACS Grant to Examine Racial Disparities in Head and Neck Cancer Patients

A team of Temple researchers led by Fox Chase epidemiologist Camille Ragin, MPH, PhD, has received a grant of more than $1.7 million from the American Cancer Society (ACS) to examine how genetics and the environment interact to influence racial disparities in patients with head and neck cancer. A founding member of the African-Caribbean Cancer Consortium (AC3), since 2006 Ragin has investigated the prevalence and outcomes of cancer for different racial groups in the United States and abroad. Continue Reading »

Comments Off

Heat Shock Protein 90 Inhibitors Investigated as Therapeutic Agents

Based on research at Fox Chase that has illuminated heat shock protein 90 (HSP90) as a potentially important therapeutic target in several diseases, translational researchers are launching clinical studies to test the efficacy of therapies that inhibit this protein. HSP90 mediates activity for numerous cell-signaling pathways and transcription factors, and is over-expressed in cancerous cells. Continue Reading »

Next Page »